AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
AbbVie announced its acquisition of Apogee Therapeutics for $10.9 billion. The deal aimed to strengthen AbbVie's immunology portfolio, with a focus on long-acting autoimmune drugs.
Epilogue added 19d ago, after coverage quieted.
The brief
AbbVie has entered into an agreement to acquire Apogee Therapeutics for $10.9 billion. The deal is designed to integrate Apogee's long-acting immunology and inflammation (I&I) drug candidates into AbbVie's existing portfolio.
Coverage from the WSJ, Stat News, and Fierce Biotech emphasizes the deal's valuation and AbbVie's interest in a specific eczema prospect described as "hotly tipped." The transaction was also confirmed via the AbbVie News Center and Endpoints News. Future developments will center on the integration of Apogee's drug candidates and the progress of the eczema prospect.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 22d ago.
Quick answers
How much is AbbVie paying for Apogee Therapeutics?
The acquisition is valued at $10.9 billion.
What specific therapeutic area is the target of this acquisition?
The deal focuses on immunology and inflammation (I&I), specifically long-acting drug candidates and an eczema prospect.
Which outlets reported on this deal?
The acquisition was reported by the WSJ, Stat News, Fierce Biotech, Endpoints News, and the AbbVie News Center.
Coverage (12)
- Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders Morningstar · 22d ago
- AbbVie paying $10.9B to buy Waltham biotech NBC Boston · 22d ago
- ABBV: Acquisition adds high-value immunology assets with blockbuster potential and long-term growth prospects TradingView · 22d ago
- AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion Yahoo Finance · 22d ago
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 22d ago
- Done deal: AbbVie to buy Apogee for $10.9B FirstWord Pharma · 22d ago
- AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · 22d ago
- AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect Fierce Biotech · 22d ago
- AbbVie to buy Apogee Therapeutics in nearly $11B deal statnews.com · 22d ago
- AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidates Endpoints News · 22d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 22d ago
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News Center · 22d ago
Topics
Related trends
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the publication of pharmaceutical rejection letters, issuing 14 new Complete Response Letters following a three-month pause.
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks, aiming to increase supply chain transparency.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning
Public scrutiny regarding the mental, physical, and legal implications of GLP-1 receptor agonists intensifies amid reports of potential litigation.
AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
The First AI‑Designed Vaccine Has Been Tested in People. Here’s What Happened.
Clinical trials for the world's first AI-designed vaccine have entered human testing, marking a potential shift in medical development methodology.